BioArctic AB (OSTO:BIOA B)
kr 238.4 5 (2.14%) Market Cap: 21.06 Bil Enterprise Value: 20.57 Bil PE Ratio: 0 PB Ratio: 21.21 GF Score: 55/100

Q3 2019 BioArctic AB Earnings Call Transcript

Oct 24, 2019 / 07:30AM GMT
Release Date Price: kr92.5 (+1.82%)
Operator

Hello, and welcome to the BioArctic Q3 Report 2019. (Operator Instructions)

Today, I'm pleased to present CEO, Gunilla Osswald; and CFO, Jan Mattsson. So please go ahead with your meeting.

Gunilla Osswald;publ;CEO
BioArctic AB

()-

Welcome to BioArtic's interim report from January to September. I'm Gunilla Osswald and I'm the CEO of BioArtic, and I'm happy to do the presentation here today and share it with our CFO, Jan Mattsson.

Next slide, please. This is our disclaimer. And BioArtic is listed on NASDAQ.com midcap.

Next slide, please. For those of you who are new to BioArtic, I will start with a short introduction to the company. And BioArtic is a unique Swedish biopharma company. By that, I put it into 4 different areas. I start with that we are working on areas where there is a high unmet medical need in CNS. Today, there are only symptomatic treatments for Alzheimer's disease and Parkinson's disease and we focus on disease-modifying treatments, and these are areas where there is a growing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot